Vestal Point Capital LP Invests $3.77 Million in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Vestal Point Capital LP has invested approximately $3.77 million in Kiniksa Pharmaceuticals International, acquiring 169,864 shares during the first quarter.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share, exceeding analysts' expectations, with revenue of $156.80 million in its latest quarter.
• Wall Street analysts have maintained a positive outlook on Kiniksa, with a consensus price target of $41.17 and several analysts issuing "buy" ratings.

Vestal Point Capital LP bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 169,864 shares of the company's stock, valued at approximately $3,773,000. Vestal Point Capital LP owned approximately 0.23% of Kiniksa Pharmaceuticals International at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Birchview Capital LP bought a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $666,000. Cubist Systematic Strategies LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth $4,663,000. Kodai Capital Management LP acquired a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth $4,117,000. State of Wyoming grew its stake in shares of Kiniksa Pharmaceuticals International by 15.3% in the first quarter. State of Wyoming now owns 17,064 shares of the company's stock worth $379,000 after purchasing an additional 2,258 shares during the last quarter. Finally, Trexquant Investment LP increased its holdings in Kiniksa Pharmaceuticals International by 192.5% in the first quarter. Trexquant Investment LP now owns 236,483 shares of the company's stock valued at $5,252,000 after purchasing an additional 155,641 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on KNSA shares. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 30th. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of "Buy" and an average target price of $41.17.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 17,000 shares of the business's stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $32.35, for a total value of $549,950.00. Following the transaction, the chief accounting officer directly owned 33,041 shares of the company's stock, valued at approximately $1,068,876.35. The trade was a 33.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Eben Tessari sold 138,614 shares of the stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the transaction, the chief operating officer directly owned 49,915 shares of the company's stock, valued at $1,657,178. This represents a 73.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 558,403 shares of company stock valued at $18,078,671 in the last quarter. 53.48% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock traded up $0.20 on Friday, reaching $35.71. 328,234 shares of the company were exchanged, compared to its average volume of 429,216. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $35.84. The company has a market cap of $2.65 billion, a price-to-earnings ratio of 892.97 and a beta of 0.20. The company has a 50-day moving average of $30.95 and a 200-day moving average of $26.49.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.